ClinicalTrials.gov
public full text
Public Domain
A Study of TAK-881 and HyQvia in Healthy Adults
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)#290874
- A Study of TAK-861 in People With Narcolepsy Type 1#843948
- Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants#832487
- Prevalence of Inappropriate Prescriptions and Omitted Therapies in Hospitalized Elderly: STOPP/START Criteria Analysis#843424
- A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants#811033
Record · ID 889410
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive